Showing 1–10 of 10 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Amira Mahmood, Mohammad Bilal Ashfaq, Catherine Drain, Eoin Melby, Michael Hunter, et al.
Tuberculosis remains the biggest global killer from infectious causes, with an estimated 1.25 million deaths per year. The quadruple drug regimen of rifampicin, isoniazid, pyrazinamide, and ethambutol has been standard therapy for 40 years, with good outcomes in patients with dru…
Simone Villa, Giovanni Battista Migliori, Lia D’Ambrosio, Mario Raviǵlione
Tuberculosis is an infectious disease caused by bacteria of the Mycobacterium tuberculosis complex that are transmitted through air droplets from persons with pulmonary tuberculosis. Once exposed, a person might become infected but only 5–10% of them will, eventually, develop the…
Alina Malic, Adriana Niguleanu, Tatyana Osipov
Treatment of tuberculosis (TB) includes various therapeutic regimens with a combination of at least four drugs. Adherence to the treatment regimen is crucial for efficacy outcomes based on the achievement of appropriate drug levels. Drug-resistant () strains are mainly favored by…
Usharani Brammachary, Venkateswari Ramachandra, Suganthi Palavesam, Vidya Raj Cuppusamy Kapalamurthy, Aaina Muralidhar, et al.
Tuberculosis (TB) remains the most challenging infection to treat worldwide. The contemporary TB regimens consist of 6–9 months of daily doses of four drugs in the existing regimen that is extremely toxic to patients. The purpose of these longer treatments is to eliminate Mycobac…
Marcela Muñóz-Torrico, Norma A. Téllez-Navarrete, Heinke Kunst, Linh Nguyen
The main goals of this chapter are to establish tuberculosis (TB) treatment goals, how and when to start anti-TB treatment, discuss the recommended regimens for drug sensitive TB. Establish recommended doses of the primary regimen, and finally recommended treatment adjustment in …
Jamal Hassan Mohamoud
Tuberculosis (TB) remains a major public health concern in Somalia, driven by prolonged conflict, population displacement, fragile health systems, and adverse social determinants of health. Although Somalia has made progress in expanding TB services and achieving favourable treat…
Xiaoyun Du, Keqing Shi, Hao Zhang, Yingzhi Chong
Tuberculosis (TB) remains a leading global health threat, with the rise of drug-resistant (DR-TB) strains posing a significant impediment to disease control. An increasingly recognized and complex challenge is heteroresistance, the coexistence of drug-susceptible and drug-resista…
Sarah Schmidiger, Damien Portevin
(), the causative agent of tuberculosis (TB), has plagued humankind for millennia. Claiming 1.25 million lives in 2023, TB remains the worldwide leading cause of death from a single-infectious agent. Improved vaccines, diagnostics and treatment regimens for drug-susceptible and d…
Aisya Rezki Noeriman, Sumarheni Sumarheni, Aliya Nur Hasanah, Lika Apriani, Prayudi Santoso, et al.
…ved outcomes. However, evidence supporting its benefits for tuberculosis (TB) treatment remains limited. This scoping review evaluated clinical studies on TDM and its impact on TB treatment outcomes. **METHODS:** A scoping review was performed using a systematic search in PubMed…
John W Wilson, Zelalem Temesgen, James T Gaensbauer
…been published for both drug-susceptible and drug-resistant tuberculosis (TB), TB in children, and contacts of patients with drug-resistant TB. The operationalization and application of these recommendations, which reflect favorable clinical trial outcomes, may vary significantly…